MA47130B1 - Anticorps se liant spécifiquement à l'il-15 humaine et leurs utilisations - Google Patents

Anticorps se liant spécifiquement à l'il-15 humaine et leurs utilisations

Info

Publication number
MA47130B1
MA47130B1 MA47130A MA47130A MA47130B1 MA 47130 B1 MA47130 B1 MA 47130B1 MA 47130 A MA47130 A MA 47130A MA 47130 A MA47130 A MA 47130A MA 47130 B1 MA47130 B1 MA 47130B1
Authority
MA
Morocco
Prior art keywords
human
specifically binding
antibodies specifically
antibodies
dysregulation
Prior art date
Application number
MA47130A
Other languages
English (en)
French (fr)
Other versions
MA47130A (fr
Inventor
Matthew Pollard
Anthony Gerard Doyle
David Jose Simon LAINE
Lynn Dorothy Poulton
Adam William Clarke
Original Assignee
Cephalon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon, Inc. filed Critical Cephalon, Inc.
Publication of MA47130A publication Critical patent/MA47130A/fr
Publication of MA47130B1 publication Critical patent/MA47130B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5443—IL-15

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
MA47130A 2016-12-21 2017-12-21 Anticorps se liant spécifiquement à l'il-15 humaine et leurs utilisations MA47130B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437143P 2016-12-21 2016-12-21
PCT/US2017/067917 WO2018119246A1 (en) 2016-12-21 2017-12-21 Antibodies that specifically bind to human il-15 and uses thereof
EP17883800.9A EP3558369B1 (en) 2016-12-21 2017-12-21 Antibodies that specifically bind to human il-15 and uses thereof

Publications (2)

Publication Number Publication Date
MA47130A MA47130A (fr) 2019-10-30
MA47130B1 true MA47130B1 (fr) 2025-05-30

Family

ID=62627610

Family Applications (1)

Application Number Title Priority Date Filing Date
MA47130A MA47130B1 (fr) 2016-12-21 2017-12-21 Anticorps se liant spécifiquement à l'il-15 humaine et leurs utilisations

Country Status (30)

Country Link
US (2) US11267883B2 (cg-RX-API-DMAC7.html)
EP (2) EP3558369B1 (cg-RX-API-DMAC7.html)
JP (2) JP7155126B2 (cg-RX-API-DMAC7.html)
KR (2) KR20190097094A (cg-RX-API-DMAC7.html)
CN (1) CN110234349B (cg-RX-API-DMAC7.html)
AR (1) AR110414A1 (cg-RX-API-DMAC7.html)
AU (2) AU2017382850B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019012570A8 (cg-RX-API-DMAC7.html)
CA (1) CA3046387A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019001729A1 (cg-RX-API-DMAC7.html)
DK (1) DK3558369T3 (cg-RX-API-DMAC7.html)
EA (1) EA201991514A1 (cg-RX-API-DMAC7.html)
ES (1) ES3026508T3 (cg-RX-API-DMAC7.html)
FI (1) FI3558369T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20250482T1 (cg-RX-API-DMAC7.html)
HU (1) HUE071878T2 (cg-RX-API-DMAC7.html)
IL (1) IL267113B2 (cg-RX-API-DMAC7.html)
LT (1) LT3558369T (cg-RX-API-DMAC7.html)
MA (1) MA47130B1 (cg-RX-API-DMAC7.html)
MD (1) MD3558369T2 (cg-RX-API-DMAC7.html)
MX (2) MX2019007357A (cg-RX-API-DMAC7.html)
PE (1) PE20191497A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019501453A1 (cg-RX-API-DMAC7.html)
PL (1) PL3558369T3 (cg-RX-API-DMAC7.html)
PT (1) PT3558369T (cg-RX-API-DMAC7.html)
RS (1) RS66900B1 (cg-RX-API-DMAC7.html)
SI (1) SI3558369T1 (cg-RX-API-DMAC7.html)
UA (1) UA126284C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018119246A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201903848B (cg-RX-API-DMAC7.html)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2815099T3 (es) 2013-08-05 2021-03-29 Twist Bioscience Corp Genotecas sintetizadas de novo
CA2975852A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
WO2016172377A1 (en) 2015-04-21 2016-10-27 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
EP3350314A4 (en) 2015-09-18 2019-02-06 Twist Bioscience Corporation OLIGONUCLEIC ACID VARIANT LIBRARIES VARIANT AND SYNTHESIS THEREOF
KR102794025B1 (ko) 2015-09-22 2025-04-09 트위스트 바이오사이언스 코포레이션 핵산 합성을 위한 가요성 기판
JP6871364B2 (ja) 2016-09-21 2021-05-12 ツイスト バイオサイエンス コーポレーション 核酸に基づくデータ保存
PT3558369T (pt) 2016-12-21 2025-05-06 Cephalon Llc Anticorpos que se ligam especificamente à il-15 humana e suas utilizações
CN110892485B (zh) 2017-02-22 2024-03-22 特韦斯特生物科学公司 基于核酸的数据存储
AU2018284227B2 (en) 2017-06-12 2024-05-02 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
JP2020536504A (ja) 2017-09-11 2020-12-17 ツイスト バイオサイエンス コーポレーション Ｇｐｃｒ結合タンパク質およびその合成
CN111565834B (zh) 2017-10-20 2022-08-26 特韦斯特生物科学公司 用于多核苷酸合成的加热的纳米孔
KR102804057B1 (ko) 2018-01-04 2025-05-07 트위스트 바이오사이언스 코포레이션 Dna 기반 디지털 정보 저장
EP3814497A4 (en) 2018-05-18 2022-03-02 Twist Bioscience Corporation POLYNUCLEOTIDES, REAGENTS AND METHODS FOR NUCLEIC ACID HYBRIDIZATION
US12459980B2 (en) 2018-07-25 2025-11-04 AskGene Pharma, Inc. IL-21 prodrugs and methods of use thereof
US11828385B2 (en) 2018-12-25 2023-11-28 Ntn Corporation Flow control valve seal and flow control valve device
CA3124980A1 (en) 2018-12-26 2020-07-02 Twist Bioscience Corporation Highly accurate de novo polynucleotide synthesis
CA3131689A1 (en) 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for glp1 receptor
AU2020227802A1 (en) 2019-02-26 2021-10-14 Twist Bioscience Corporation Variant nucleic acid libraries for antibody optimization
CA3141626A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
WO2020257612A1 (en) 2019-06-21 2020-12-24 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
EP4034564A4 (en) 2019-09-23 2023-12-13 Twist Bioscience Corporation VARIANT NUCLEIC ACID LIBRARIES FOR SINGLE-DOMAIN ANTIBODIES
EP4034566A4 (en) 2019-09-23 2024-01-24 Twist Bioscience Corporation VARIANT NUCLEIC ACID BANKS FOR CRTH2
WO2021119193A2 (en) * 2019-12-09 2021-06-17 Twist Bioscience Corporation Variant nucleic acid libraries for adenosine receptors
JP2023545821A (ja) * 2020-10-16 2023-10-31 ジェネンテック， インコーポレイテッド 抗ｉＣａｓｐａｓｅ切断基質抗体および使用方法
CA3206018A1 (en) 2021-01-21 2022-07-28 Twist Bioscience Corporation Methods and compositions relating to adenosine receptors
CN113185600A (zh) * 2021-05-28 2021-07-30 苏州复融生物技术有限公司 一种新型白介素15突变体多肽的开发及其应用
WO2024028448A1 (en) 2022-08-04 2024-02-08 Calypso Biotech Sa Il-15 inhibitors useful for the treatment of atopic dermatitis
CN118894934A (zh) * 2023-05-05 2024-11-05 北京智仁美博生物科技有限公司 抗人il-15的抗体及其用途
CN117209605B (zh) * 2023-11-09 2024-01-30 北京百普赛斯生物科技股份有限公司 特异性结合il-15的抗体及其应用
WO2025227052A1 (en) * 2024-04-26 2025-10-30 Cephalon Llc Doses and formulations of anti-il-15 antibody for the treatment of immune diseases

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
US7132510B2 (en) * 2000-12-29 2006-11-07 Bio-Technology General (Israel) Ltd. Specific human antibodies for selective cancer therapy
US7247304B2 (en) * 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
US7329405B2 (en) * 2001-08-23 2008-02-12 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
DK1425389T3 (da) * 2001-08-23 2012-01-30 Genmab As Interleukin-15-(IL-15)-specifikke humane antistoffer
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7285269B2 (en) * 2002-12-02 2007-10-23 Amgen Fremont, Inc. Antibodies directed to tumor necrosis factor
EA015897B1 (ru) * 2003-02-26 2011-12-30 Генмаб А/С Применение человеческого моноклонального антитела к ил-15 в составе композиции и лекарственного препарата (варианты), композиция и лекарственный препарат, его включающие
TW200613552A (en) * 2004-08-11 2006-05-01 Hoffmann La Roche Mutant interleukin-15 polypeptides
AU2006216291B2 (en) * 2005-02-27 2011-01-27 Institute For Antibodies Co., Ltd. Anti-IgSF4 antibody and utilization of the same
EP1896582A4 (en) * 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS
PT2336329E (pt) 2007-06-01 2012-12-24 Omt Inc Composições e métodos para inibição de genes de imunoglobulina endógena e produção de anticorpos transgénicos humanos idiotípicos
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
NO2792236T3 (cg-RX-API-DMAC7.html) 2009-07-08 2018-04-14
EP2488201A4 (en) * 2009-10-15 2013-12-25 Abbvie Inc IL-1 BINDING PROTEINS
EP2550529B1 (en) 2010-03-23 2021-11-17 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
JP5972871B2 (ja) * 2010-07-20 2016-08-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｉｌ−２３ヘテロ二量体特異的抗体
JP5820688B2 (ja) 2011-03-23 2015-11-24 株式会社Kri 多糖類の溶解に用いられる溶媒ならびに該溶媒を用いた成形体および多糖類誘導体の製造方法
JP2014534806A (ja) * 2011-08-23 2014-12-25 ロシュ グリクアート アーゲー 抗ｍｃｓｐ抗体
ES3033729T3 (en) * 2011-10-28 2025-08-07 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
WO2014131694A1 (en) * 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
EP2963057A1 (en) * 2014-07-02 2016-01-06 Calypso Biotech SA Antibodies to IL-15
NZ736026A (en) 2015-03-31 2023-02-24 Medimmune Ltd A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
MX2024001374A (es) * 2016-06-15 2024-02-27 Amgen Inc Anticuerpo anti-il-15 o fragmento de union a antigeno del mismo, para usarse en el tratamiento de la enfermedad celiaca, de la sensibilidad al gluten no celiaca y de la enfermedad celiaca refractaria.
MA46534A (fr) 2016-10-14 2019-08-21 Xencor Inc Protéines de fusion fc hétérodimères il15/il15r
PT3558369T (pt) 2016-12-21 2025-05-06 Cephalon Llc Anticorpos que se ligam especificamente à il-15 humana e suas utilizações

Also Published As

Publication number Publication date
DK3558369T3 (da) 2025-05-19
BR112019012570A2 (pt) 2019-11-26
CN110234349B (zh) 2024-03-22
PT3558369T (pt) 2025-05-06
US20200270339A1 (en) 2020-08-27
SI3558369T1 (sl) 2025-06-30
AU2017382850A1 (en) 2019-07-04
CL2019001729A1 (es) 2019-09-13
JP2020501583A (ja) 2020-01-23
US12410247B2 (en) 2025-09-09
MX2019007357A (es) 2019-09-05
PL3558369T3 (pl) 2025-06-23
JP2022176324A (ja) 2022-11-25
KR20190097094A (ko) 2019-08-20
RS66900B1 (sr) 2025-07-31
AR110414A1 (es) 2019-03-27
LT3558369T (lt) 2025-07-25
MD3558369T2 (ro) 2025-08-31
KR20230135691A (ko) 2023-09-25
PH12019501453A1 (en) 2020-06-15
CA3046387A1 (en) 2018-06-28
JP7155126B2 (ja) 2022-10-18
UA126284C2 (uk) 2022-09-14
WO2018119246A1 (en) 2018-06-28
MX2023014081A (es) 2023-12-06
IL267113B1 (en) 2024-05-01
EP4585261A3 (en) 2025-08-13
IL267113B2 (en) 2024-09-01
KR102706743B1 (ko) 2024-09-19
IL267113A (en) 2019-08-29
EA201991514A1 (ru) 2019-12-30
AU2017382850B2 (en) 2024-11-21
FI3558369T3 (fi) 2025-05-02
ES3026508T3 (en) 2025-06-11
EP4585261A2 (en) 2025-07-16
ZA201903848B (en) 2023-02-22
PE20191497A1 (es) 2019-10-21
AU2025201185A1 (en) 2025-03-13
HUE071878T2 (hu) 2025-09-28
BR112019012570A8 (pt) 2023-01-24
EP3558369A4 (en) 2020-09-09
MA47130A (fr) 2019-10-30
US11267883B2 (en) 2022-03-08
EP3558369A1 (en) 2019-10-30
US20220127352A1 (en) 2022-04-28
HRP20250482T1 (hr) 2025-06-20
EP3558369B1 (en) 2025-03-26
CN110234349A (zh) 2019-09-13

Similar Documents

Publication Publication Date Title
MA47130B1 (fr) Anticorps se liant spécifiquement à l'il-15 humaine et leurs utilisations
TN2019000099A1 (en) Anti-lag-3 antibodies and compositions
MA34555B1 (fr) Nouvelles protéines de liaison à un antigène
CA3156451A1 (en) Antibodies having specificity for nectin-4 and uses thereof
SA521422581B1 (ar) أil-7r جسام مضادة للوحدة الثانوية ألفا واستخداماتها
MA39313A1 (fr) Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers
SG10201914119TA (en) Anti-b7-h3 antibodies and antibody drug conjugates
WO2018229236A3 (en) COMPOSITIONS COMPRISING BACTERIAL STRAINS
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
MA42622B1 (fr) Agents de liaison à tigit et leurs utilisations
MA49726B1 (fr) Formulation d'anticorps anti-cgrp
MA34461B1 (fr) Anticorps anti-peptide beta-amyloide n3pgiu et leurs utilisations
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
PH12014502184A1 (en) Anti-hla-b* 27 antibodies and uses thereof
MA38183A1 (fr) Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase
MA35365B1 (fr) Pyrimidines annelées substituées et leur utilisation
JO3462B1 (ar) أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
MA31904B1 (fr) Anticorps bispecifiques bivalents
MX2019008434A (es) Muteínas de lipocalina con afinidad de unión por lag-3.
MA43088A1 (fr) Anticorps anti-il-17c
MA38369A1 (fr) Peptides et compositions pour le traitement d'une lesion de l'articulation
EP3682898A4 (en) PHARMACEUTICAL COMPOSITION WITH AN ANTIBODY SPECIFICALLY BINDING THE LYSYL-TRNA SYNTHETASE-N TERMIN, AS AN EFFECTIVE INGREDIENT IN THE PREVENTION OR TREATMENT OF IMMUNE CELL MIGRATION RELATED DISEASE
EP3878867A4 (en) Antibody binding to human il-1 ?, preparation method therefor and use thereof
MA39555B1 (fr) Mutagenèse dirigée d'anticorps trem-1 pour réduire la viscosité
MA47976B1 (fr) Anticorps dirigés contre trem2 et leur utilisation